Cancer research often takes place behind closed laboratory doors, in images, models and experiments that rarely reach the public. With Tiny Revelations, Professor Anne Rios wants to change that.

Oncode researcher Megan Farrell has received a Veni grant to study how signals from surrounding tissue affect immune cell activity.

Evaluation confirms that Oncode Institute is a proven infrastructure that connects fundamental cancer research with value for patients, healthcare, science and the economy.

As Managing Director, Bertholt helps guide Oncode's long-term direction while supporting the people and collaborations that make its work possible. In this Employee Spotlight, he shares what drives his work, the projects that inspire him most and the experiences outside the office that help him recharge.

Oncode Institute congratulates Prof. René Bernards on receiving the People’s Republic of China International Science and Technology Cooperation Award.

The GLOW study shows that Whole Genome Sequencing can support treatment decisions for recurrent glioblastoma while highlighting the challenges of translating genomic insights into clinical care.

The Oncode Impact Foundation, a joint initiative of Oncode Accelerator Foundation and Oncode Institute, launched today. It uses philanthropy to fund the development of new treatment options for cancer patients through the so-called ‘valley of death’: the crucial phase in which promising scientific breakthroughs often falter and fail to reach patients.

Researchers led by Oncode Investigator Nitika Taneja have uncovered how cells reorganise the structure of their DNA to protect it when replication is disrupted. The findings, published in Nature, provide new insight into a fundamental process that helps maintain genome stability.

Oncode Investigators Leila Akkari and Puck Knipscheer have been elected as EMBO Members, recognising their outstanding scientific achievements and contributions to the life sciences.

In its Annual Report 2025, published today, Oncode Institute shows how excellent fundamental cancer research, collaboration and valorisation together drive impact for patients, society and the economy. The number of people living with cancer continues to rise, pressure on healthcare systems is increasing, and the need for effective and affordable diagnostics and treatments is growing. At the same time, the Netherlands is home to world-class cancer research. The challenge is to translate that knowledge faster and more effectively into applications that reach patients.

Oncode Investigator Jurgen Marteijn has been awarded an ERC Advanced Grant for his project GeneGuard, which will investigate how cells detect, signal and resolve transcription stress caused by DNA damage. 

KWF Dutch Cancer Society and Oncode Institute are taking an important next step in their collaboration. Together, both organisations are working towards a future-proof model to further strengthen fundamental cancer research and innovation in the Netherlands. 

The KWF Dutch Cancer Society and Oncode Institute today announced they are joining forces to develop a future-proof approach to fundamental cancer research in the Netherlands. Together, they are building on a proven model in which excellent science, collaboration and valorisation reinforce one another, with the aim of creating greater room for breakthroughs that can ultimately benefit patients. 

Making pancreatic tumours visible during surgery and turning immune cells inside the body into targeted cancer fighters. With two new research projects, KiKa, Oncode Institute and KWF Kankerbestrijding are investing in innovative treatments for rare cancers in adults and children. 

A breakthrough from the Hubrecht Institute and Oncode Institute is set to redefine how proteins are produced from mRNA offering new opportunities for biotech and pharmaceutical companies to enhance performance across a wide range of applications.